Arrowhead price target raised to $48 from $45 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Arrowhead (ARWR) to $48 from $45 and keeps an Equal Weight rating on the shares. Redemplo’s approval in FCS last week “importantly sets the stage for meaningful label expansion into SHTG,” the analyst tells investors. Phase 3 SHASTA 3 & 4 studies of plozasiran in SHTG are on track for Q3 of 2026 and management pointed to “a decent chance for success on pancreatitis,” the analyst added.